CorFlow Therapeutics Completes Phase 1, Launches Phase 2 MOCA II Trial, and Expands Clinical Leadership
CorFlow Therapeutics Reports Phase 1 Completion, Initiates Phase 2 Enrollment in MOCA II Trial, Gains EU Approval for REVITALISE RCT, and Expands Clinical Leadership CorFlow Therapeutics AG has announced a…
FDA Advisory Panel Backs TRUQAP® (Capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
FDA Advisory Committee Backs TRUQAP® (capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee has delivered a largely favorable assessment of TRUQAP,…
Summit Therapeutics Announces First-Quarter 2026 Financial Results and Highlights Key Operational Advancements
Summit Therapeutics Announces Q1 2026 Financial Results and Highlights Key Operational Achievements Summit Therapeutics Inc. (NASDAQ: SMMT) has reported its financial results for the first quarter ended March 31, 2026,…
Acadia Pharmaceuticals Announces Year-End Retirement of R&D Head Elizabeth H.Z. Thompson, Ph.D.
Acadia Pharmaceuticals Plans Year-End Retirement of R&D Chief Elizabeth H.Z. Thompson After Distinguished Career Acadia Pharmaceuticals Inc. has announced that Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development,…
Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain
Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on advancing differentiated therapies…
Corcept’s Phase 2 Trial of Dazucorilant Shows Two-Year Survival Advantage in Amyotrophic Lateral Sclerosis Patients
Corcept’s Phase 2 Trial of Dazucorilant Shows Sustained Two-Year Survival Advantage in ALS Patients Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on developing therapies that modulate cortisol…
Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate
Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in…
TRexBio Initiates Phase 1b Study of TRB-061 with First Patient Dosed in Moderate-to-Severe Atopic Dermatitis
TRexBio Initiates Phase 1b Study of TRB-061 in Moderate-to-Severe Atopic Dermatitis with First Patient Dosed TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on discovering and developing immunoregulatory therapies…
U.S. FDA Grants Priority Review to Gilead’s NDA for Once-Daily HIV Regimen Combining Bictegravir and Lenacapavir
U.S. FDA Accepts Priority Review for Gilead’s Once-Daily HIV Therapy Combining Bictegravir and Lenacapavir Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its New…
Convergent Therapeutics Appoints Andrew Davis as Chief Business and Strategy Officer
Convergent Therapeutics Appoints Andrew Davis as Chief Business and Strategy Officer Convergent Therapeutics, a clinical-stage biotech company dedicated to advancing next-generation radiopharmaceutical therapies for cancer, has announced the appointment of…
Cosette Pharmaceuticals Names Erika Tooman SVP & General Counsel to Support Growth Strategy
Cosette Pharmaceuticals Names Erika Tooman as Senior Vice President and General Counsel, Enhancing Leadership to Support Growth and Strategic Expansion Cosette Pharmaceuticals, a U.S.-based branded specialty pharmaceutical company, has announced…
ClearNote Health to Showcase Advanced Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026
ClearNote Health to Showcase Leading Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 ClearNote Health, a biotechnology company focused on advancing early cancer detection, has…